Publications and Presentations

Corvus is committed to driving science and medicine and helping patients. We promptly and efficiently communicate our preclinical and clinical findings to the scientific, medical and patient communities because we believe disseminating knowledge and information is good for patients.

Our scientists and clinical trial investigators have published the following research papers in peer-reviewed journals and presented the following data at scientific congresses.

Presentations

Selective ITK Blockade Modulates T Helper Cell Function and Is Efficacious in Preclinical Models of T-cell Mediated Inflammatory Disease

Rahul D. Pawar1, Lih-Yun Hsu1, Dan Li1, Poorva Ghosh1, James T. Rosenbaum1, 2, Richard A. Miller1

 1Corvus Pharmaceuticals, Burlingame, CA, 2Legacy Devers Eye Institute, Portland, OR.

Poster presentation at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

Dynamic Single-Cell Profiling Reveals Novel Immune Regulatory Mechanism of ITKi Soquelitinib in Refractory T Cell Lymphoma​

Ning Ding1, Yan Xie1, Yong Guo2, Kecheng Li2, Tingting DU1, Zhenjun Li1, Yuejiao Li1, Jiaowu Cao1, Dingyao Hu1, Lih-Yun Hsu3, Richard Miller3, Jun Zhu1 and Yuqin Song, MD1​

1Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China;​ 2Angel Pharmaceuticals Co., Ltd., Jiaxing, China; ​3Corvus Pharmaceuticals Inc, Burlingame, United States of America

Poster presentation at American Society of Hematology (ASH) 2023

Selective A2AR Blockade Synergizes with Immune Checkpoint Therapy by Potentiating Proinflammatory Th1 Helper Cell Responses

Dan Li, Poorva Ghosh, Lih-Yun Hsu, Richard A. Miller

Corvus Pharmaceuticals, Inc., Burlingame, California, United States

Poster presentation at the Japanese Cancer Association and American Association for Cancer Research (JCA-AACR) Precision Cancer Medicine International Conference

Itk Inhibitor induces Th1 skewing and host anti-tumor response mediated by CD8+ TEMRA cells in refractory T cell lymphoma patients

N. Ding1, Y. Xie1, J. Reneau2, R. Miller3, S. Mahabhashyam3, L. Hsu3, Y. Guo4, K.C. Li4, T. Du1, L. Mi1, N. Lin1, J. Cao1, D. Hu1, D. Wang1, Y. Li1, Z. Li1, J. Zhu1, Y. Song1

1Peking University Cancer Hospital, Department of Lymphoma, Beijing, China; 2The Ohio State University and Wexner Medical Center, Columbus, Ohio, United States of America; 3Corvus Pharmaceuticals Inc., Burlingame, California, United States of America; 4Angel Pharmaceuticals Co., Ltd., Jiaxing, China

Poster presentation at the International Conference on Malignant Lymphoma (ICML) Meeting

Selective ITK blockade induces antitumor responses and enhances efficacy to immune checkpoint inhibitors in preclinical models

Lih-Yun Hsu1, Rahul Pawar1, Dan Li1, Poorva Ghosh1, Kevin Nguyen1, Carlene Williams1, Yuqin Song2, Ning Ding2, Erik Verner3, and Richard Miller1,3

1Corvus Pharmaceuticals, Inc, Burlingame, CA, USA; 2Peking University Cancer Hospital & Institute, Beijing, China; 3Angel Pharmaceuticals Co., Ltd, Jiaxing, China

Poster presentation at the American Association for Cancer Research 2023, Orlando, FL

ITK Inhibition in T-cell Lymphomas

John Reneau, MD, PhD, The Ohio State University Comprehensive Cancer Center

Presentation at the 10th Whistler Global Summit on Hematologic Malignancies

Interleukin-2-Inductible T-Cell Kinase (ITK) Inhibition Prevents HIV Latency Reversal

Prerna Dabral1,2, Li Du1,2, Mohamed S. Bouzidi1,2, Richard Miller3, Steven G. Deeks4, Satish K. Pillai1,2

1Vitalant Research Institute, San Francisco, CA, USA; 2Department of Laboratory Medicine, University of California, San Francisco, CA, USA; 3Corvus Pharmaceuticals, Burlingame, CA, USA; 4School of Medicine, University of California, San Francisco, CA, USA

Poster presentation at the 30th Annual Conference on Retroviruses and Opportunistic Infections (CROI), February 2023, Seattle, WA.

ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and is Active in Refractory T Cell Lymphomas

Poster presentation

Slide presentation

Yuqin Song1, Ning Ding1, Dok Hyun Yoon2, John Reneau3, Ryan Wilcox4, Won Seog Kim5, Youn Kim6, Michael Khodadoust6, Tatyana Feldman7, Costas K Yannakou8, Pratyush Giri9, Jonathan Brammer3, Lih-Yun Hsu10, Hongwei Yuan10, Erik Verner11, Suresh Mahabhashyam10, Richard Miller10,11

1Peking University Cancer Hospital & Institute, Beijing, China; 2Asan Medical Center, Seoul, South Korea; 3The Ohio State University and Wexner Medical Center, Columbus, OH, USA; 4University of Michigan, Ann Arbor, MI, USA; 5Samsung Medical Center, Seoul, South Korea; 6Stanford Cancer Institute, Stanford, CA, USA; 7John Theurer Cancer Center at HMH, Hackensack, NJ, USA; 8Epworth HealthCare, Melbourne, Victoria, Australia; 9Royal Adelaide Hospital, Adelaide, South Australia, Australia; 10Corvus Pharmaceuticals Inc, Burlingame, CA, USA; 11Angel Pharmaceuticals Co., Ltd, Jiaxing, China

Poster Presentation at the 2022 American Society of Hematology Annual Meeting

Highly Selective Irreversible ITK Inhibitor CPI-818 Reduces Acute Graft-Versus Host Disease

S. Lindner1, N. Lee1, G. Armijo1, M. Burgos Da Silva1, P. S. Herrera1, C. Nguyen1, E.A. Dwomoh1, R. Ghale1, M. Smith2, Ma. Perales3, K.A. Markey4, J. J. Buggy5, J. W. Janc5, M. R. M. Van Den Brink1,3

1 Department of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Memorial Sloan Kettering Cancer Center, New York, NY, USA 2 Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA 3 Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington Fred Hutchinson Cancer Research Center, Seattle, Washington, USA 5 Corvus Pharmaceuticals Inc., Burlingame, CA, USA

Poster presentation at the 2021 American Society of Hematology Annual Meeting

Activating CD73 on B cells as a target for immunotherapy of COVID-19 and viral associated cancers: Clinical activity in human papilloma virus positive (HPV) head and neck squamous cell cancers (HNSCC)

Jason J. Luke; Jaime R. Merchan, MD; Brett GM. Hughes, MD; Jeffrey A. Sosman, MD; Abhishek Tripathi, MD; Igor Puzanov, MD, MSCI; Thomas U. Marron, MD, PhD; Kristen A. Marrone, MD; Craig M. Hill, PhD; James Janc, PhD; Jenny Rudnick, BS, PhD; Shenshen Hu, PhD; Mehrdad Mobasher, MD, MPH; Suresh Mahabhashyam, MD, MPH; Richard A. Miller, MD

Poster presentation at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

The ITK Inhibitor CPI-818 Blocks Activation of T Cells from Autoimmune Lymphoproliferative Syndrome (ALPS) Patients and is Active in a Murine Model of ALPS

V Koneti Rao2, Patrick P Ng1, Craig M Hill1, Richard A Miller1, Joseph J Buggy1, and James W Janc1

1Corvus Pharmaceuticals, Inc., Burlingame, CA; 2ALPS Unit, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH, Bethesda, MD

Poster Presentation at the 2020 American Society of Hematology (ASH) 62nd Annual Meeting

CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, is Well-Tolerated and Active in Patients with T-Cell Lymphoma

Khodadoust M1, Feldman T2, Yoon DH3, Yannakou C4, Radeski D5, Kim YH6, Mehta-Shah N7, Khot A8, Wilcox R9, Kim WS10, Horwitz S11, Buggy J12, Hotson A12, Hill C12, Munneke B12, Mahabhashyam S12, Miller R12, Janc J12 and Mobasher M12

1Division of Medical Oncology, Stanford University School of Medicine, Stanford, CA; 2John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; 3Asan Medical Center/University of Ulsan College of Medicine, Seoul, Korea, Republic of (South); 4Epworth HealthCare, Melbourne, Australia; 5Linear Clinical Research and Sir Charles Gairdner Hospital, Nedlands, Australia; 6Stanford University School of Medicine and Stanford Cancer Institute, Stanford, CA; 7Division of Medical Oncology, Washington University School of Medicine, St Louis, MO; 8Department of Clinical Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia; 9University of Michigan, Ann Arbor, MI; 10Hematology and Oncology, Department of Medicine, Samsung Medical Center, Seoul, Korea, Republic of (South); 11Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY; 12Corvus Pharmaceuticals, Inc., Burlingame, CA

Poster presentation at the 2020 American Society of Hematology (ASH) 62nd Annual Meeting

Immunotherapy with B cell activating antibody CPI-006 in patients with mild to moderate COVID-19 stimulates anti-SARS-CoV-2 antibody response, memory B cells, and memory T effector cells

Gerard Criner, M.D., Chair & Professor, Thoracic Medicine & Surgery, Lewis Katz School of Medicine at Temple University

Oral presentation at the 2020 Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting

Immunotherapy with B cell activating antibody CPI-006 in patients with mild to moderate COVID-19 stimulates anti-SARS-CoV-2 antibody response, memory B cells, and memory T effector cells

Criner G1, Mobasher M2, Hill C2, Hu S2, Mahabhashyam S2, Brody J3, Marron T3, Willingham S2, Miller R2

1Temple University Hospital, Philadelphia, PA, USA; 2Corvus Pharmaceuticals Inc, Burlingame, CA, USA; 3Icahn School of Medicine at Mount Sinai, New York, NY, USA 

Poster presentation at the 2020 Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting

CD68+ Tumor-Associated Myeloid Cells as the Target of Adenosine-Induced Gene Products and Predictor of Response to Adenosine Blockade with Ciforadenant (Cifo) in Renal Cell Cancer (RCC)

Voss M1, Hotson A2, Willingham S2, Hughes B3, Mercan J4, Fong L5, Chu M6, George S7, Munneke B2, Mobasher M2, Miller R2

1Memorial Sloan Kettering Cancer Center, New York NY, 2Corvus Pharmaceuticals, Burlingame CA, 3Royal Brisbane Hospital, Brisbane Australia, 4Sylvester Comprehensive Cancer Center, Miami FL, 5UCSF Comprehensive Cancer Center, San Francisco CA, 6Cross Cancer Institute, Alberta Canada, 7Roswell Park Cancer Institute, Buffalo NY

Poster presentation at the American Society of Clinical Oncology ASCO20 Virtual Scientific Program

Adenosine Receptor Blockade with Ciforadenant ± Atezolizumab in Advanced Metastatic Castration Resistant Prostate Cancer (mCRPC)

Fong L1, Chu M2, George S3, Hughes B4, Carthon B5, Merchan J6, Harshman L7, Munneke B8, Kwei L8, Hotson A8, Mobasher M8, Miller R8

1UCSF Comprehensive Cancer Center, San Francisco CA, 2Cross Cancer Institute, Alberta Canada, 3Roswell Park Cancer Institute, Buffalo NY, 4Royal Brisbane Hospital, Brisbane Australia, 5Winship Cancer Institute, Atlanta GA, 6Sylvester Comprehensive Cancer Center, Miami FL, 7Dana-Farber Cancer Institute, Boston MA, 8Corvus Pharmaceuticals, Burlingame CA

Poster presentation at the American Society of Clinical Oncology 2020 Genitourinary Cancers Symposium (ASCO-GU)

CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor
Pre-clinical Characterization and Interim Results of a Phase I/Ib Dose-Escalation Trial in Patients with Relapsed/Refractory T-Cell Lymphoma

Mehrdad Mobasher, MD, MPH Chief Medical Officer

Oral Presentation at the 12th Annual T-Cell Lymphoma Forum in La Jolla, California, February 1, 2020

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, A Selective ITK Inhibitor that Preferentially Blocks the Growth of T Lymphoma Cells 

Patrick P. Ng, PhD, Corvus Senior Scientist

Poster Presentation at the American Society of Hematology (ASH) 61st Annual Meeting 2019

Immunobiology and Clinical Activity of CPI-006, an Anti-CD73 Antibody with Immunomodulating Properties in a Phase 1/1b Trial in Advanced Cancers

Jason J. Luke, M.D., FACP, Director of the Cancer Immunotherapeutics Center, Associate Professor of Medicine, the University of Pittsburgh Medical Center and Hillman Cancer Center

Oral presentation at 2019 Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

Adenosine and AMP Gene Expression Profiles Predict Response to Adenosine Pathway Therapies and Indicate a Need for Dual Blockade of CD73 and A2AR with CD73 Inhibitors

Stephen Willingham, PhD, Corvus Senior Scientist

Poster Presentation at 2019 Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

Immunobiology, Preliminary Safety and Efficacy of CPI-006, an Anti-CD73 Antibody with Immune Modulating Activity, in a Phase 1 Trial in Advanced Cancers

Jason J. Luke*, John D. Powderly II, Jaime R. Merchan, Minal A. Barve, Andrew N. Hotson, Mehrdad Mobasher, Long Kwei, Gabriel Luciano, Joseph J. Buggy, Emily Piccione, Richard A. Miller

University of Chicago Comprehensive Cancer Center, Chicago, IL; Carolina BioOncology Institute, Huntersville, NC; University of Miami, Miami, FL; Mary Crowley Cancer Research Center, Dallas, TX; Corvus Pharmaceuticals Inc, Burlingame, CA

*Currently at University of Pittsburgh Medical Center 

Oral presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

Biochemical, Immunologic and In Vivo Preclinical Studies with CPI-818: A Selective Interleukin-2-Inducible T-cell Kinase Inhibitor That Inhibits T-Cell Receptor Signaling, Promotes Th1 Skewing, and is Efficacious in Dogs with T-Cell Lymphomas

James W Janc1,*, C M Hill1, P P Ng1, A N Hotson1, A Madriaga1, T P Dao-Pick1, K S Yeung1, E Verner1, D H Thamm2, R A Miller1 and J J Buggy1

1 Corvus Pharmaceuticals, Burlingame CA, USA. 2 Flint Animal Cancer Center, Colorado State University, Fort Collins, CO, USA.

Poster presentation at the 11th Annual T-cell Lymphoma Forum, La Jolla, CA, January 10-12, 2019

Interleukin-2-Inducible T-cell Kinase Inhibitors for the Treatment of T-cell Lymphoproliferative Disorders

John C. Reneau, MD, PhD1, Steven R. Hwang, MD2, Carlos A. Murga-Zamalloa, MD1, Joseph J. Buggy, PhD3, James W. Janc, PhD3 and Ryan A. Wilcox, MD, PhD1

1 University of Michigan, Ann Arbor, MI; 2 Mayo Clinic, Rochester, MN; 3 Corvus Pharmaceuticals, Inc., Burlingame, CA

Poster presentation at 60th Annual ASH Meeting, San Diego, CA, Dec 1-4th 2018

CPI-818: A Selective Interleukin-2-Inducible T-cell Kinase Inhibitor Has Clinical Activity in Dogs with Spontaneous T-cell Lymphoma

Douglas H. Thamm,1 Kristen M. Weishaar,1 Sunetra Das,1 Antonett Madriaga,2 Craig M. Hill,2 Felicia M. Flicker,2 Bradley H. Wolfe,2 Patrick P. Ng,2 Andrew N. Hotson,2 Richard A. Miller,2 Joseph J. Buggy,2 James W. Janc2

1 Flint Animal Cancer Center, Colorado State University, Fort Collins, CO USA; 2 Corvus Pharmaceuticals, Burlingame, CA USA

Poster presentation at 30th EORTC-NCI-AACR Symposium, Molecular Targets and Cancer Therapeutics, Dublin IE, Nov 13-16th 2018

Refractory Renal Cell Cancer (RCC) Exhibits High Adenosine A2A Receptor (A2AR) Expression and Prolonged Survival Following Treatment With the A2AR Antagonist CPI-444

Lawrence Fong, M.D., University of California, San Francisco

Oral presentation at 2018 Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting

Preclinical and initial Phase I clinical characterization of CPI-006: an anti-CD73 monoclonal antibody with unique immunostimulatory activity

Emily Piccione, Ph.D., Corvus Pharmaceuticals

Poster presentation at 2018 Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting

Adenosine signature genes associate with tumor regression in renal cell carcinoma (RCC) patients treated with the adenosine A2A receptor (A2AR) antagonist, CPI-444

Drew Hotson, Ph.D., Corvus Pharmaceuticals

Poster presentation at 2018 Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting

Identification of Adenosine Pathway Genes Associated with Response to Therapy with the Adenosine Receptor Antagonist CPI-444

Willingham S1, Hotson A1, Laport G1, Kwei L1, Fong L2, Sznol M3, Powderly J4, Miller R1

1 Corvus Pharmaceuticals, Burlingame CA, USA, 2 University of California, San Francisco CA, USA, 3 Yale University School of Medicine, New Haven CT, USA, 4 Carolina BioOncology Institute, Huntersville NC, USA

Poster presentation at 2018 European Society for Medical Oncology (ESMO) 2018 Congress

Identification of Adenosine Pathway Genes Associated with Response to Therapy with the Adenosine Receptor Antagonist CPI-444

Stephen Willingham, Ph.D., Corvus Pharmaceuticals

Slide presentation at 2018 European Society for Medical Oncology (ESMO) 2018 Congress

Preclinical Study of Investigational Small Molecule T-cell Signaling Pathway Inhibitor in Companion Dogs Diagnosed with T-cell Lymphoma

Ryan Wilcox, M.D., Ph.D., Assistant Professor at the University of Michigan Comprehensive Cancer Center

Oral presentation at 10th Annual T-Cell Lymphoma Forum (2018)

Clinical Activity of Adenosine A2a Receptor (A2aR) Inhibitor CPI-444 is Associated with Tumor Expression of Adenosine Pathway Genes and Tumor Immune Modulation

Jason J. Luke, M.D., FACP, Assistant Professor of Medicine, University of Chicago Medicine

Oral presentation at Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting (2017)

Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients

Lawrence Fong, M.D., Leader, Cancer Immunotherapy Program, Co-Director, Parker Institute of Cancer Immunotherapy, University of California, San Francisco

Oral presentation at American Society of Clinical Oncology (ASCO) 2017 Annual Meeting

CPI-444, an oral adenosine A2a receptor (A2AR) antagonist, demonstrates clinical activity in patients with advanced solid tumors

Leisha Emens, M.D., Ph.D., Associate Professor of Oncology, John Hopkins Sidney Kimmel Comprehensive Cancer Center

Oral Presentation at American Association for Cancer Research (AACR) 2017 Annual Meeting

Inhibition of A2AR induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical and clinical studies

Stephen Willingham, Ph.D., Corvus Pharmaceuticals 

Poster Presentation at American Association for Cancer Research (AACR) 2017 Annual Meeting

Adenosine signaling through A2AR limits the efficacy of anti-CTLA4 and chemotherapy in preclinical models

Po Y. Ho, Corvus Pharmaceuticals 

Poster Presentation at American Association for Cancer Research (AACR) 2017 Annual Meeting

A novel CD73-blocking antibody reduces production of immunosuppressive adenosine and restores T-cell function

Emily Piccione, Ph.D., Corvus Pharmaceuticals 

Poster Presentation at American Association for Cancer Research (AACR) 2017 Annual Meeting

Publications

The following contains links to certain websites owned and operated by third parties. If you use these links you leave our website. These links are provided for your information and convenience only and are not an endorsement by Corvus Pharmaceuticals, Inc. of the content of such linked websites. Corvus has no control of the content of any linked website and is not responsible for these websites or their content or availability. Corvus therefore makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by or the information contained on them.

Synthesis and characterization of soquelitinib a selective ITK inhibitor that modulates tumor immunity

Lih-Yun Hsu, James T. Rosenbaum, Erik Verner, William B. Jones, Craig M. Hill, James W. Janc, Joseph J. Buggy, Rahul D. Pawar, Poorva Ghosh, Dan Li, Ning Ding, John C. Reneau, Michael S. Khodadoust, Youn H. Kim, Ryan A. Wilcox, and Richard A. Miller

npj Drug Discov. 1, 2 (2024). doi: 10.1038/s44386-024-00002-1

Soquelitinib, A Selective Inhibitor of Interleukin- 2-Inducible T Cell Kinase (ITK), is Active in Several Murine Models of T Cell-Mediated Inflammatory Disease

Lih-Yun Hsu, James T. Rosenbaum, Sarah Lindner, Yannick Allanore, Anne Cauvet, Rahul D. Pawar, Dan Li, Marcel Van Den Brink, and Richard A. Miller

bioRxiv doi: 10.1101/2023.10.27.564296

Selective Inhibition of Interleukin-2 Inducible T Cell Kinase (ITK) Enhances Anti-Tumor Immunity in Association with Th1-skewing, Cytotoxic T cell Activation, and Reduced T Cell Exhaustion

Lih-Yun Hsu, James T Rosenbaum, Erik Verner, William B Jones, Craig M. Hill, James W. Janc, Joseph J. Buggy, Ning Ding, John C. Reneau, Michael S. Khodadoust, Youn H. Kim, Ryan A. Wilcox, and Richard A. Miller

bioRxiv doi: 10.1101/2023.07.05.547822

Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer

Richard A Miller, Jason John Luke, Shenshen Hu, Suresh Mahabhashyam, William B Jones, Thomas Marron, Jaime R Merchan, Brett G M Hughes, and Stephen B. Willingham

Journal for ImmunoTherapy of Cancer 2022;10:e005802. doi: 10.1136/jitc-2022-005802

Clinical Results with a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19

Richard A. Miller, Pramod Guru, Philippe Bauer, Jorge Robles, Christian Tomaszewski, J. Scott Overcash, Michael Waters, Miriam Cameron,Julián Olalla Sierra, James Janc, Jenny A. Rudnick, Shenshen Hu, William B. Jones, Long Kwei, Suresh Mahabhashyam, Stephen B. Willingham, and Gerard Criner

medRxiv doi: 10.1101/2021.09.13.21263406v1

Therapeutic blockade of CXCR2 rapidly clears inflammation in arthritis and atopic dermatitis models: demonstration with surrogate and humanized antibodies

Md Jahangir Alam, Liang Xie, Caroline Ang, Farnaz Fahimi, Stephen B. Willingham, Andrew J. Kueh, Marco J. Herold, Charles R. Mackay, and Remy Robert

mAbs, 2020 12:1, DOI: 10.1080/19420862.2020.1856460

Targeting the A2AR in Cancer; Early Lessons From the Clinic

Willingham SB, Hotson AN, Miller RA

Curr. Opin. Pharmacol. 2020, 53:126–133.

Characterization and Phase 1 Trial of a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19

Stephen B. Willingham, Gerard Criner, Craig Hill, Shenshen Hu, Jenny A. Rudnick, Barbara Daine-Matsuoka, Jessica Hsieh, Haider Mashhedi, Andrew N. Hotson, Joshua Brody, Thomas Marron, Emily Piccione, Joseph J. Buggy, Suresh Mahabhashyam, William B. Jones, Mehrdad Mobasher, and Richard A. Miller

medRxiv doi: 10.1101/2020.09.10.20191486

Our Science

We are developing ITK inhibition as a new approach to control the immune system in order to treat immune diseases and cancer

Join Our Team

Contribute your talent, expertise and desire to learn here at Corvus, where you can help improve the lives of people with immune diseases and cancer